JP5792066B2 - ポルフィラジン並びに光学的及びデュアル光学的/mrコントラスト並びに治療薬 - Google Patents
ポルフィラジン並びに光学的及びデュアル光学的/mrコントラスト並びに治療薬 Download PDFInfo
- Publication number
- JP5792066B2 JP5792066B2 JP2011526218A JP2011526218A JP5792066B2 JP 5792066 B2 JP5792066 B2 JP 5792066B2 JP 2011526218 A JP2011526218 A JP 2011526218A JP 2011526218 A JP2011526218 A JP 2011526218A JP 5792066 B2 JP5792066 B2 JP 5792066B2
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- compound
- optical
- porphyrazine
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K51/0451—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. phorphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
- A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/122—Macromolecular compounds dimers of complexes or complex-forming compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
- A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Description
Mは、2H又はピロール窒素原子と複合体を形成し得る金属イオンであり、
nは、1〜3であり、
Aは、(−N(R1)2)2、(−OR1)2、又は(−SR1)2であり、
Bは、pzに結合した、一つ又はそれ以上の−XR2基で置換されたベンゾ環であり、ここでXはO又はSであり、
R1は各々独立に、また、R2は各々独立に、OH、OR3、N(R3)2、CO2R3、又はCON(R3)2で随意に置換されたC1-6アルキル、OH、OR3、N(R3)2、CO2R3、又はCON(R3)2で随意に置換されたC3-6シクロアルキル、OH、OR3、N(R3)2、CO2R3、又はCON(R3)2で随意に置換された(CH2)1-3C3-6シクロアルキル、OH、OR3、N(R3)2、CO2R3、又はCON(R3)2で随意に置換されたCH2)1-6C6H5からなる群から選択される基であり、ここで、各R3は、独立してH、C1-6アルキル、C3-6シクロアルキル、又は(CH2)1-3C3-6シクロアルキル;
(iv)1−アジド−3−アミノプロパン、CH2Cl2;(v)ビス(2−アジドエチル)アミン、CH2Cl2
Claims (2)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9502608P | 2008-09-08 | 2008-09-08 | |
US61/095,026 | 2008-09-08 | ||
PCT/US2009/055991 WO2010028216A2 (en) | 2008-09-08 | 2009-09-04 | Porphyrazine optical and dual optical/mr contrast and therapeutic agents |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012502052A JP2012502052A (ja) | 2012-01-26 |
JP2012502052A5 JP2012502052A5 (ja) | 2012-12-13 |
JP5792066B2 true JP5792066B2 (ja) | 2015-10-07 |
Family
ID=41429276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011526218A Expired - Fee Related JP5792066B2 (ja) | 2008-09-08 | 2009-09-04 | ポルフィラジン並びに光学的及びデュアル光学的/mrコントラスト並びに治療薬 |
Country Status (4)
Country | Link |
---|---|
US (1) | US8540967B2 (ja) |
EP (2) | EP2599497A3 (ja) |
JP (1) | JP5792066B2 (ja) |
WO (1) | WO2010028216A2 (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100317966A1 (en) * | 2009-06-05 | 2010-12-16 | Institut National D'optique | Hybrid-multimodal magneto-optical contrast markers |
PT2593127T (pt) * | 2010-07-13 | 2018-07-06 | Georgia State Univ Research Foundation | Agente antiangiogénico e método de usar esses agente |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
BR112014012444B1 (pt) | 2011-11-23 | 2021-12-14 | Therapeuticsmd, Inc | Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20160031909A1 (en) * | 2013-03-12 | 2016-02-04 | Hoffman/Barrett, Llc | Porphyrazine optical and dual optical/ mr contrast and therapeutic agents |
JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 天然の併用ホルモン補充療法剤及び療法 |
WO2016162229A1 (en) | 2015-04-10 | 2016-10-13 | Capsugel Belgium N.V. | Abiraterone acetate lipid formulations |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
EP3435977A4 (en) | 2016-04-01 | 2019-10-16 | Therapeuticsmd, Inc. | PHARMACEUTICAL COMPOSITION OF STEROID HORMONE |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2764605B1 (fr) * | 1997-06-17 | 2004-03-26 | Univ Hyderabad | Molecules hybrides d'un photosensibilisateur et d'un agent chimiotherapeutique, leur procede de production et leur application collaterale en chimiotherapie et therapie photodynamique |
US20020155999A1 (en) * | 1998-04-30 | 2002-10-24 | Han In Suk | Method of using a porphyrin-like molecule conjugated with an anti-cancer drug for the treatment of cancer |
US20040192665A1 (en) * | 2002-08-02 | 2004-09-30 | Slil Biomedical Corporation | Conjugates of porphyrin compounds with chemotherapeutic agents |
JP4855937B2 (ja) * | 2003-05-14 | 2012-01-18 | ソシエテ デ コマーシャリセーション デス プロデューツ デ ラ リーサーシェ アプリケ エスオーシーピーアールエー−サイエンセス サンテ エ ヒューマネス エス.イー.シー. | 医療における光線力学適用のための両親媒性トリスルホン化ポルフィラジン |
-
2009
- 2009-09-04 US US13/062,031 patent/US8540967B2/en not_active Expired - Fee Related
- 2009-09-04 EP EP13156925.3A patent/EP2599497A3/en not_active Withdrawn
- 2009-09-04 JP JP2011526218A patent/JP5792066B2/ja not_active Expired - Fee Related
- 2009-09-04 EP EP09792260A patent/EP2340041A2/en not_active Withdrawn
- 2009-09-04 WO PCT/US2009/055991 patent/WO2010028216A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
JP2012502052A (ja) | 2012-01-26 |
EP2599497A3 (en) | 2013-09-25 |
US20110293531A1 (en) | 2011-12-01 |
WO2010028216A3 (en) | 2011-01-06 |
WO2010028216A2 (en) | 2010-03-11 |
US8540967B2 (en) | 2013-09-24 |
EP2599497A2 (en) | 2013-06-05 |
EP2340041A2 (en) | 2011-07-06 |
WO2010028216A8 (en) | 2011-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5792066B2 (ja) | ポルフィラジン並びに光学的及びデュアル光学的/mrコントラスト並びに治療薬 | |
US10780045B2 (en) | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof | |
US10806694B2 (en) | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof | |
JP5421114B2 (ja) | 低酸素症選択性の弱塩基性2−ニトロイミダゾール送達薬剤およびその使用方法 | |
US8562944B2 (en) | PAA nanoparticles for enhancement of tumor imaging | |
WO2017031084A1 (en) | Poly(vinyl alcohol) nanocarriers | |
WO2022123462A1 (en) | Radiolabelled prostate specific membrane antigen (psma) inhibitors and use thereof | |
WO2004103344A1 (en) | Combination chemotherapy comprising a liposomal platinum complex | |
CN108264514A (zh) | 一种有机物及其制备方法和应用 | |
US20160031909A1 (en) | Porphyrazine optical and dual optical/ mr contrast and therapeutic agents | |
US20200308184A1 (en) | Tetrapyrrolic conjugates and uses thereof for imaging | |
KR102621851B1 (ko) | 포피린 유도체 및 암의 영상화, 진단, 또는 치료용 조성물 | |
WO2023173074A2 (en) | Immunostimulant-cytotoxic conjugate composition and methods for cancer treatment | |
AU2022388735A1 (en) | Psma targeted conjugate compounds and uses thereof | |
KR20230067608A (ko) | 망간 화학 요법, 광음향 이미징, 및 광열 요법을 위한 텍사피린 유도체 | |
Duan et al. | Molecular persistent luminescence imaging with porphyrin derivatives for ultrasensitive image-guided cancer surgery and drug screening | |
KR20230057188A (ko) | 광반응성을 이용한 복합 항암제 조성물 및 이의 제조방법 | |
WO2023173087A1 (en) | Light-activatable, sustained-exposure ethanol injection | |
WO2024052431A1 (en) | Prostate specific membrane antigen (psma) ligands and use thereof | |
CN116406279A (zh) | 用于检测和治疗癌症的方法和试剂 | |
WO2018237136A1 (en) | CONJUGATES FOR DETECTING AXILLARY LYMPHATIC GANGLION METASTASES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120829 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121023 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131126 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140224 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140303 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140324 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20141202 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150330 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150514 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150605 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150707 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150805 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5792066 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |